NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5.73 mln
Float2.19 mln
Earnings Date11/13/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
18.50
Transformational upside
Relative Strength
100
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-150
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
GRI Bio is a US-based drug development company working to create new treatments for serious conditions involving inflammation, scarring, and immune system dysfunction. Its most advanced drug, GRI-0621, is taken by mouth and is currently being tested in mid-stage clinical trials as a potential treatment for idiopathic pulmonary fibrosis, a severe and progressive lung disease. The company also has several other drug candidates at earlier stages of development, including GRI-0803 for autoimmune conditions, along with a library of more than 500 compounds. Founded in 2009 and headquartered in La Jolla, California, GRI Bio was previously known as Glycoregimmune Inc.
